A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504571-25-00

Acronym

BP42233

Enrollment

180

Registered

2024-03-15

Start date

2020-10-20

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Denmark, France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026